BioMarin, Jazz Pharmaceuticals, and Otsuka CEOs to Join NORD Leadership for Landmark Rare Disease Dialogue at 2026 Breakthrough Summit

WASHINGTON, D.C. and NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has announced that CNBC “Squawk Box” co-anchor and “CNBC Cures” host Becky Quick will moderate a high-profile rare disease CEO leadership panel at the upcoming NORD® Rare Diseases & Orphan Products Breakthrough Summit®. The discussion will feature the chief executive officers of BioMarin, Jazz Pharmaceuticals, and Otsuka alongside NORD CEO Pam Gavin.

The flagship panel, titled “Next Decade of Rare Disease: A CEO Leadership Dialogue,” is scheduled for 11 a.m. ET on Monday, Oct. 26, in Washington, D.C. The conversation forms a centerpiece of NORD’s three-day annual event, which runs from Oct. 25 through Oct. 27. Now in its sixteenth year, the Breakthrough Summit has grown into one of the premier gatherings in the healthcare and biopharmaceutical sectors, convening more than 900 leaders from across the rare disease ecosystem to address the complex challenges shaping the future of research, treatment development, policy, care, and patient access.

This year’s dialogue comes at a pivotal and transformative juncture for the rare disease community. Rapid advancements in science, genetics, and biotechnology are creating unprecedented possibilities for early diagnosis and targeted intervention. However, industry stakeholders emphasize that scientific discovery alone is not enough. Realizing the full potential of these innovations will require regulatory frameworks, public policies, private investment, healthcare infrastructure, and treatment delivery mechanisms to keep pace with scientific breakthroughs.

The upcoming panel will examine the leadership decisions, strategic investments, and cross-sector partnerships needed to capitalize on this unique historical moment. A central theme of the discussion will be addressing the ongoing challenge of scale—specifically, how the biopharmaceutical industry and healthcare systems can successfully advance and deliver more treatments for a greater number of rare conditions.

The three participating biopharmaceutical CEOs bring diverse perspectives from global companies that maintain distinct rare disease portfolios, extensive development pipelines, and deep experience in navigating the complex pathways required to bring specialized therapies to market. Alongside them, Pam Gavin will bring NORD’s independent, cross-disease patient and systems perspective. Gavin’s participation will help connect the high-level scientific and business questions facing modern rare disease innovation with the diverse, often urgent unmet needs, daily care hurdles, and access barriers experienced by individuals living with any of the more than 10,000 known rare diseases.

CNBC’s Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD

Becky Quick brings decades of distinguished experience covering global business, finance, and markets, as well as conducting in-depth interviews with many of the world’s most influential corporate leaders. In addition to her extensive journalistic background, Quick shares a deeply personal connection to the rare disease community as a parent of a child living with a rare condition. In her role as moderator, she will weave these personal and professional perspectives together, guiding the panel to explore how leaders can maximize the promise of scientific and technological innovation and translate individual laboratory breakthroughs into widespread, sustainable progress for patients.

“We are at an important moment for rare disease. Science is opening doors that would have been unimaginable even a decade ago, but discovery alone does not ensure those advances reach the people who need them,” said Pam Gavin, CEO of NORD, addressing the urgency of the upcoming discussion. “Realizing that potential will require leadership across the rare disease ecosystem to remove barriers, keep pace with innovation and translate progress into better outcomes for more people across more rare diseases. That is why this conversation—and the Breakthrough Summit—matter right now.”

The broader programming for the 2026 Breakthrough Summit spans a wide range of critical topics, including federal health and regulatory priorities, emerging therapies and cutting-edge technologies, investment trends, patient partnership models, and the systemic frameworks required to move medical breakthroughs safely and efficiently from the laboratory bench to the patient bedside.

In addition to the CEO leadership dialogue, the 2026 conference will feature keynote remarks and interactive discussions with prominent senior federal health leaders. Among them are Kyle Diamantas, J.D., Acting Commissioner of the U.S. Food and Drug Administration (FDA), and Dr. Jay Bhattacharya, M.D., Ph.D., Director of the National Institutes of Health (NIH). Their participation underscores the vital collaboration required between federal regulators, public research agencies, private industry, and patient advocacy groups.

The NORD Breakthrough Summit is intentionally built around cross-sector collaboration to tackle complex systemic challenges that no single organization, company, or sector can solve in isolation. Comprehensive details regarding event registration, the complete speaker lineup, and the full conference agenda are available at NORDSummit.org.

Founded in 1983, the National Organization for Rare Disorders (NORD®) is a leading independent, nonpartisan, 501(c)(3) nonprofit organization dedicated to identifying, treating, and curing rare disorders through education, advocacy, research, and patient services. Representing the more than 30 million Americans living with rare diseases, NORD works in active partnership with over 350 disease-specific member patient organizations to drive meaningful progress in rare disease research, care, and public policy.

Dwi Wanna

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya